BioSniper
Earnings Reportpositive

Earnings Report

April 30, 2026
Company
ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Other upcoming events for ALNY

Phase 2 StartPhase 2 Start: HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharm
Jun 30, 2026
Phase 2 StartPhase 2 Start: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study, to Evaluate Efficacy, Sa
Jul 1, 2026
Phase 3 ReadoutPhase 3 Topline: HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the
Dec 2, 2026
Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Trans
Mar 31, 2028
Phase 3 ReadoutPhase 3 Topline: ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficac
Sep 30, 2030

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
ALNY OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About
  • Data Methodology

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle